Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection

References

• Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–1733. doi:10.1093/annonc/mdn35118515795
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. doi:10.1200/JCO.2007.15.437718565894
   PubMed Web of Science ®Google Scholar
• Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14:3492–3500. doi:10.1245/s10434-007-9566-617896148
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. doi:10.1186/1756-8722-4-2921672194
   PubMed Web of Science ®Google Scholar
• Han X, Zhang C, Tang M, et al. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol. 2015;27:527–535. doi:10.1097/MEG.000000000000033225822862
   PubMed Web of Science ®Google Scholar
• Luo G, Javed A, Strosberg JR, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine tumor society systems. J Clin Oncol. 2017;35:274–280. doi:10.1200/JCO.2016.67.819327646952
   PubMed Web of Science ®Google Scholar
• Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824–833. doi:10.1038/modpathol.2010.5820305616
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–712. doi:10.1097/MPA.0b013e3181ec124e20664470
   PubMed Web of Science ®Google Scholar
• Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204–212. doi:10.1097/SLA.0b013e31828f317423673766
   PubMed Web of Science ®Google Scholar
• Ye L, Ye H, Zhou Q, et al. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: new proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases. Int J Surg. 2016;29:108–117. doi:10.1016/j.ijsu.2016.03.03627000717
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–7803. doi:10.1158/1078-0432.CCR-08-073419047107
   PubMed Web of Science ®Google Scholar
• Wei IH, Harmon CM, Arcerito M, Cheng DF, Minter RM, Simeone DM. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2014;260:1088–1094. doi:10.1097/SLA.000000000000026225389924
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044–3049. doi:10.1200/JCO.2011.35.181721709192
   PubMed Web of Science ®Google Scholar
• Wang SE, Su C-H, Kuo Y-J, et al. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region. Pancreas. 2011;40:253–259. doi:10.1097/MPA.0b013e3181f94cc420966805
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2:472–482.9843608
   PubMedGoogle Scholar
• Sallinen V, Haglund C, Seppanen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: do size and symptoms matter? Surgery. 2015;158:1556–1563. doi:10.1016/j.surg.2015.04.03526070847
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Turrini O, Ewald J, et al. Pancreatic neuroendocrine tumor: a multivariate analysis of factors influencing survival. Eur J Surg Oncol. 2014;40:1564–1571. doi:10.1016/j.ejso.2014.06.00425086992
   PubMed Web of Science ®Google Scholar
• Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Brit J Surg. 2008;95:627–635. doi:10.1002/bjs.605118306152
   PubMed Web of Science ®Google Scholar
• Conrad C, Kutlu OC, Dasari A, et al. Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas. J Gastrointest Surg. 2016;20:1966–1974. doi:10.1007/s11605-016-3243-727714644
   PubMed Web of Science ®Google Scholar
• Liu P, Zhang X, Shang Y, et al. Lymph node ratio, but not the total number of examined lymph nodes or lymph node metastasis, is a predictor of overall survival for pancreatic neuroendocrine neoplasms after surgical resection. Oncotarget. 2017;8:89245–89255. doi:10.18632/oncotarget.1918429179516
   PubMedGoogle Scholar